Acalabrutinib demonstrated superior progression-free survival for r/r chronic lymphocytic leukaemia patients
Acalabrutinib, a next-generation selective Bruton’s tyrosine kinase (BTK) inhibitor, has been approved in the European…
Browsing: Acalabrutinib
Blood cancer drug may help treat patients with severe COVID-19
Early data from a clinical study suggest that blocking the Bruton tyrosine kinase (BTK) protein…
EHA 2019: Acalabrutinib shows remarkable benefit in relapsed or refractory chronic lymphocytic leukaemia
The Phase III ASCEND study of the Bruton’s Tyrosine Kinase inhibitor (BTKi) acalabrutinib in relapsed…